Immune recovery and late CMV infection after stem cell transplant
Part of Immune system & allergy, Infections clinical trials.
This study looks at how your immune system recovers after a stem cell transplant and whether that affects your risk of getting a late cytomegalovirus (CMV) infection. You will take letermovir, a medicine that helps prevent CMV, and the study will check your immune function when you stop taking it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have tested positive for CMV (a common virus) before your transplant.
- This is your first stem cell transplant using donor cells (allogeneic transplant).
- You start the study within 28 days after your transplant.
- You are planned to take letermovir to prevent CMV, starting within 28 days after transplant and continuing up to 100 days.
- You have not had a prior stem cell transplant from a donor (autologous transplants are okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This study tests whether a blood test can help doctors decide how long to continue letermovir (a medicine that prevents a common viral infection called CMV) after a stem cell transplant. The goal is to see if a shorter course is safe and effective for some patients.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This study checks whether certain virus levels in your blood after a stem cell transplant can help predict or prevent CMV infection. It aims to improve how doctors monitor and protect patients from this virus.
Hear when a new Cytomegalovirus Cell Mediated Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.